Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/Women benefit from lower ACE inhibitor and ARB doses
Hfref · ACEARB-HFREF-03 · v2
Four separate datasets point the same way: women with reduced-ejection-fraction heart failure appear to get their benefit from ACE inhibitors and ARBs at about half the dose that guidelines target, with little or no added gain from pushing the dose higher, whereas men do better at the full dose. This pattern shows up in a European and Asian cohort study [3], a Dutch outpatient clinic cohort [7], the Swedish national registry [10], and in a re-analysis of a trial that actually randomised patients to a low or high dose [8]. Because the finding repeats across different countries, data types, and study designs, the panel treated it as a real and consistent signal. But almost all of it comes from observational data or from after-the-fact subgroups, where the dose a patient ends up on can reflect their age, kidney function, blood pressure and body size rather than a true dose effect. No trial has deliberately randomised women to a lower versus a target dose, and the authors themselves frame the result as something to test, not to act on yet. That is why the conclusion is supported but held short of settled.
The corpus contains four datasets directly on the question. [3] reports that women had approximately 30% lower risk of death or heart-failure hospitalisation at 50% of the recommended ACE inhibitor or ARB dose with no further decrease at higher doses, a pattern replicated in the ASIAN-HF cohort. [7] found ACEI/ARB dose below 50% of target was associated with lower mortality in women but not men with HFrEF. [10] found no significant outcome difference for women between 50-99% and 100% of target dose (hazard ratio 0.92, 95% CI 0.83-1.03) while men improved with higher doses (p-interaction 0.030). The only dose-randomised evidence, [8], found women responded similarly to low and high losartan while men benefited from the high dose (interaction P=0.018), but cautioned that sex-based subgroup findings may be biased by other confounders. The contested point: The datasets consistently show no added benefit from higher doses in women, but that is equivalence, not proof that a lower dose is superior; [10]'s female hazard ratio of 0.92 crosses 1. The stronger claim that lower dose actively improves survival rests on the observational [7] alone, which is exposed to reverse causation, and [8] attributes the apparent sex effect partly to age, kidney function and symptom severity.
All 27 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
No prospective RCT randomises women with HFrEF to sub-target vs target ACEi/ARB dose; the keystone evidence ([3],[7],[10]) is observational/post-hoc, and both [8] and [10] explicitly call for such trials.
Confounding by indication: achieved dose tracks age, blood pressure, renal function and body size; [8] states that sex-based subgroup findings may be biased by other confounders (kidney function, age, symptoms), so lower-dose benefit may reflect who tolerates up-titration rather than a true dose effect.
Where it remains uncertain. Most of the data show absence of added benefit from higher dosing rather than superiority of lower dosing ([10] HR 0.92, 95% CI 0.83-1.03), and achieved dose may track confounders such as age, kidney function and body size [8].
Aleatory
Women are a minority in each dataset (e.g. 29% in [10], 30% in [8]), so sex-specific estimates carry wide intervals, with [10]'s female 50-99% vs 100% HR of 0.92 spanning 0.83-1.03.
Epistemic
No prospective RCT randomises women with HFrEF to sub-target versus target ACEi/ARB dose; [8] and [10] both call for such trials, so the key dose-response claim is untested by design.
The load-bearing papers from a corpus of 27, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Keystone cohort (BIOSTAT-CHF, replicated in ASIAN-HF) establishing the sex-specific dose-response underpinning the claim.
“In men, the lowest hazards of death or hospitalisation for heart failure occurred at 100% of the recommended dose of ACE inhibitors or ARBs and β blockers, but women showed approximately 30% lower risk at only 50% of the recommended doses, with no further decrease in risk at higher dose levels.”
Panel auditInternal validity: medium · scope of inference: Optimal ACEi/ARB dose by sex in European and Asian HFrEF patients with EF<40%.Key limitations: post-hoc observational, dose not randomised · residual confounding by indication/tolerability · hypothesis-generating by authors' framing
Independent Dutch outpatient cohort reproducing the lower-dose survival association in women specifically.
“Lower ACEI/ARB dose was associated with improved survival in women with HFrEF.”
Panel auditInternal validity: low · scope of inference: ACEI/ARB dose and all-cause mortality by sex among HFrEF patients in Dutch outpatient cardiology clinics.Key limitations: small HFrEF subgroup · observational, dose not randomised · no effect size or CI in abstract
Only dose-randomised evidence (HEAAL reanalysis); strengthens causal reading that women gain no benefit from up-titration.
“Men appeared to have benefited more from high-dose than from low-dose losartan, whereas women appeared to have responded similarly to low and high doses [hazard ratio (95% confidence interval) comparing high- vs. low-dose losartan for the composite outcome of all-cause death or all-cause hospitalization: 0.89 (0.81-0.98) in men and 1.10 (0.95-1.28) in women; interaction P = 0.018].”
Panel auditInternal validity: medium · scope of inference: Losartan low versus high dose response by sex in HFrEF.Key limitations: post-hoc sex subgroup · sex confounded with renal function, age, severity · single ARB (losartan) only
Found no sex difference in captopril pharmacokinetics or haemodynamic response, undercutting the sex-based dosing rationale for this drug.
Panel auditInternal validity: low · scope of inference: Sex differences in single-dose captopril PK/PD in healthy young adults.Key limitations: n=24 healthy volunteers · single dose, PK surrogate not outcomes · one ACEi, not HFrEF
4 of 27 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, independent, partly dose-randomised evidence supports the claim but every source is observational or a non-pre-specified subgroup with acknowledged residual confounding, so it clears Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No randomised sex-specific dose trial. The entire claim rests on observational and post-hoc data; whether a lower dose causally matches a target dose in women is untested. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective RCT randomising women with HFrEF to sub-target versus guideline-target ACEi/ARB dose with mortality and HF-hospitalisation endpoints.
Open question: Does a sub-target ACEi/ARB dose yield outcomes at least equivalent to the guideline-target dose in women with HFrEF? Why it is still open: All supporting data are observational [3], [7], [10] or a post-hoc subgroup [8]; no trial randomises dose within women.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19